Despite a strong start to the final quarter of 2019 with 17 deals pricing in October, the new issuance market slowe… https://t.co/jg45TMKONv
Q1 Securities Finance Quarterly Review
Welcome to the Securities Finance Review for Q1 2019. Two commentary features from the review are excerpted below. The full report is available for download via the link at the bottom of this page. Feedback is welcome and appreciated, please direct to email@example.com
Q1 Revenue Update
- Lending revenues improve 3% compared with Q4 2018
- Government bond balances and revenues decline
- EUR denominated corporate bonds in demand
- Asia remains bright spot for equity lending, particularly Japan & South Korea
Global securities lending revenues for Q1 2019 came in at $2.4bn; 10 percent lower than Q1 2018, and 3% higher than Q4 2018. Equity lenders have seen a lack of special balances, while there has been some marginal cooling in previously hot market segments, including: government bonds, corporate bonds and ETFs. The revenues are within the range of the preceding four quarters, however the breakdown of returns continues to evolve along with the changing needs of market participants.
2018 delivered the most securities lending revenues since the financial crisis, which looks like a tough act to follow in the early going of 2019. The last two quarters have been notable in that there hasn't been the pickup in borrow demand which often accompanies periods of increased volatility. Most recently, in Q4 2015 - Q1 2016, US equities had the two best post-crisis revenue quarters amid the credit and equity sell-off as investors hedged and added to shorts. There was no such increased demand in Q4, though there is some cause for optimism. Q1 revenues at least mounted some sequential growth relative to Q4 and key revenue drivers remain in place: Asian Emerging Markets, North American Cannabis and global credit.
(Continued in the full report)
Hooray for Exchange Offers!
When Eli Lilly announced it would spin off the remainder of its stake in Elanco Animal Health, ears perked up on securities lending desks. Exchange offers reflect the key role that securities lending plays in the plumbing of global financial markets, which we'll discuss in some detail here. This corporate action type is also boon to the securities lending industry itself, driving significant loan balances and fees. One industry veteran recently quipped that an advocacy group ought to be formed to raise awareness of exchange offers in corporate boardrooms.
Elanco Animal Health was spun off from Eli Lilly in September of last year, at which time $1.5bn of ELAN shares were floated. On February 8th, seeking to complete the divestiture, Eli Lilly offered their shareholders an opportunity to tender LLY shares in exchange for ELAN shares, the latter offered at a 7% discount to incentivize participation.
This type of incentive also attracts arbitrageurs who will buy shares with the intention of tendering them. In theory this position could be hedged by shorting ELAN shares, which would lock in the 7% discount. There's a catch. Not all tendered shares will be accepted, so arbs need to estimate the percentage of their tendered shares which will be accepted and hedge those shares with a short position in ELAN. That leaves their position in LLY shares which aren't accepted, so they need to hedge that as well by effecting a short position in LLY shares, or "boxing" their position, which can be done with synthetic products.
The hedging activity on the part of arbitrageurs causes borrow demand for both securities to increase. The real driver of lending revenue comes from the LLY shares; In forgoing the opportunity to tender shares, lenders can charge a premium to lend their holdings. These shares are referred to as "take no action" or TNA shares and are typically auctioned off to borrowers.
The scale is massive. Fully 44% of the outstanding shares of LLY were tendered, reflecting a market value greater than $57bn. The corresponding borrow in LLY shares to hedge that position reached $33bn, while the ELAN borrow balances reached $2.7bn.
(Continued in full report)
IHS Markit provides industry-leading data, software and technology platforms and managed services to tackle some of the most difficult challenges in financial markets. We help our customers better understand complicated markets, reduce risk, operate more efficiently and comply with financial regulation.
Follow Financial Services
- Corporate Bond Pricing Data, November 2019 Recap
- Cloud 2.0 – What to expect in financial services
- Due Diligence 2.O: How Vendor Risk Assessment Will Evolve
- Payments for Research – The View from Frankfurt
- Protests to weigh on Hong Kong SAR's dividend outlook
- Securities Lending Q3 Review
- Muni Monthly Summary - October 2019
- Employee spotlight: Tozar Gandhi, The Bond Buyer’s rising star
Alex Golbin, head of Assessment for KY3P at IHS Markit discusses the snowballing challenge of vendor assessments an… https://t.co/6mCs4W26Xu
New issuance was in full swing in the first week of December with 26 deals priced for total proceeds of $4.7B. Down… https://t.co/WZx4xuN3m6